Carrier-free self-assembled nanomedicine based on celastrol and galactose for targeting therapy of hepatocellular carcinoma via inducing ferroptosis

Xin Zhang,Yao Chen,Xiao Li,Hong Xu,Jirui Yang,Chuanqi Wang,Chaozheng Zhang,Yun Deng,Aiping Lu,Chuan Zheng,Jun Lu
DOI: https://doi.org/10.1016/j.ejmech.2024.116183
IF: 7.088
2024-02-06
European Journal of Medicinal Chemistry
Abstract:Triggering ferroptosis is a potential therapeutic pathway and strategy for the prospective treatment of lethal hepatocellular carcinoma (HCC). The asialo-glycoprotein receptor (ASGPR) is an over-expressed receptor on the membranes of hepatocellular carcinoma cells (HCCs) and binds specifically to galactose ( Gal ) ligand. Celastrol ( CE ) is a potent anticancer natural product, but its poor water solubility and severe toxicity restrict its clinical application. In this study, a carrier-free self-assembled nanoparticles, CE-Gal-NPs , were designed and prepared by nanoprecipitation method, which could recognize ASGPR receptor by active targeting ( Gal ligand) and passive targeting (EPR effect), access to the cell through the clathrin pathway and finally internalize to lysosomes. CE-Gal-NPs triggered reactive oxygen species (ROS)-mediated ferroptosis pathway and exerted anti-HCC effects in vitro and in vivo by down-regulating GPX4 and up-regulating COX-2 expression, depleting glutathione (GSH) levels, and increasing lipid peroxidation levels in cells and tumor tissues. In the H22 xenograft mouse model, the CE-Gal-NPs group exhibited dramatically superior tumor inhibition than the CE group, while Gal conjugating diminished the systemic toxicity of CE . Consequently, this study presented a promising strategy for CE potentiation and toxicity reduction, as well as a potential guideline for the development of clinically targeted therapeutic agents for HCC.
chemistry, medicinal
What problem does this paper attempt to address?